Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | SELE | P16581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152975 | 0.79 | KDM4C (0.50) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL24015128 | 0.76 | KDM4C (0.42) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL25107990 | 0.76 | KDM4C (0.42) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL1808138 | 0.74 | MEN1 (0.49) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL2251531 | 0.73 | KDM4C (0.41) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL22275507 | 0.73 | KDM4C (0.41) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL22275457 | 0.73 | KDM4C (0.41) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL24006607 | 0.73 | KDM4C (0.41) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL9533696 | 0.73 | MEN1 (0.44) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL28490862 | 0.73 | KDM4C (0.44) | KDM4CL3MBTL1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131483-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | HANSEN PETER | 2009-05-21 | — | — | US | disclosed |
| EP-1861370-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006098683-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131483-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | SERPINB1, ELANE, MPO | KDM4C 2815/4885L3MBTL1 3999/4885NPC1 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.